Back to Products
Retatrutide
LOT: SYN-24-25363-C

Retatrutide

Retatrutide is a synthetic triple incretin agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, representing the most advanced multi-pathway metabolic peptide currently in clinical research. Its triple receptor mechanism expands beyond dual-incretin approaches by incorporating glucagon receptor agonism, which significantly amplifies energy expenditure and lipid metabolism beyond what is achievable with GLP-1 or GIP alone. In preclinical and early clinical research, retatrutide demonstrated superior weight reduction compared to semaglutide (24.1% vs 19.7%) and showed significant improvements in renal function, lipid profiles, and pro-inflammatory cytokine suppression in metabolic disease models. It represents the frontier of incretin-based metabolic and obesity research.

Research Benefits

  • Activates GLP-1, GIP, and glucagon receptors simultaneously, amplifying energy expenditure and caloric burn beyond dual-pathway approaches
  • Demonstrates superior body weight reduction (24.1% average) and lipid profile improvements compared to GLP-1 monotherapy in research models
  • Suppresses pro-inflammatory cytokines (TNF-α, caspase-1, NLRP3) and supports renal and hepatic function in metabolic disease research

Size

Quantity

Total Price$168.68
Retatrutide is a synthetic triple incretin agonist targeting GLP-1, GIP, and glucagon receptors, representing the next evolution beyond dual-agonist metabolic compounds. It was developed by Eli Lilly as part of a research program exploring whether glucagon receptor co-agonism could further amplify the metabolic effects of incretin-based therapy. Since its development, retatrutide has been studied in controlled preclinical and clinical settings for its potential influence on energy expenditure, appetite regulation, body composition, and systemic metabolic pathway dynamics.